Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Janna Josephus Anna Oda Schoenmaekers; Marthe Sentijna Paats; Anne-Marie Clasina Dingemans; Lizza Elisabeth Lucia Hendriks

doi:10.21037/tlcr-20-459

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans^*, Lizza Elisabeth Lucia Hendriks

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Pages (from-to)	2599-2617
Number of pages	19
Journal	Translational Lung Cancer Research
Volume	9
Issue number	6
DOIs	https://doi.org/10.21037/tlcr-20-459
Publication status	Published - Dec 2020

Keywords

Non-small cell lung cancer (NSCLC)
central nervous system metastases (CNS metastases)
oligometastatic disease
tyrosine kinase inhibitors (TKIs)
DABRAFENIB PLUS TRAMETINIB
POSITIVE SOLID TUMORS
EML4-ALK FUSION GENE
HIGH-DOSE ERLOTINIB
BRAIN METASTASES
OPEN-LABEL
EGFR-MUTATION
LEPTOMENINGEAL METASTASES
CEREBROSPINAL-FLUID
1ST-LINE TREATMENT

Access to Document

10.21037/tlcr-20-459Licence: CC BY-NC-ND

Cite this

Schoenmaekers, Janna Josephus Anna Oda ; Paats, Marthe Sentijna ; Dingemans, Anne-Marie Clasina ; Hendriks, Lizza Elisabeth Lucia. / Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer : how to treat and when?. In: Translational Lung Cancer Research. 2020 ; Vol. 9, No. 6. pp. 2599-2617.

@article{dc8df3fda69c42cdaa6ca4261450b69c,

title = "Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?",

keywords = "Non-small cell lung cancer (NSCLC), central nervous system metastases (CNS metastases), oligometastatic disease, tyrosine kinase inhibitors (TKIs), DABRAFENIB PLUS TRAMETINIB, POSITIVE SOLID TUMORS, EML4-ALK FUSION GENE, HIGH-DOSE ERLOTINIB, BRAIN METASTASES, OPEN-LABEL, EGFR-MUTATION, LEPTOMENINGEAL METASTASES, CEREBROSPINAL-FLUID, 1ST-LINE TREATMENT",

author = "Schoenmaekers, {Janna Josephus Anna Oda} and Paats, {Marthe Sentijna} and Dingemans, {Anne-Marie Clasina} and Hendriks, {Lizza Elisabeth Lucia}",

year = "2020",

month = dec,

doi = "10.21037/tlcr-20-459",

language = "English",

volume = "9",

pages = "2599--2617",

journal = "Translational Lung Cancer Research",

issn = "2226-4477",

publisher = "AME Publishing Company",

number = "6",

}

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer : how to treat and when? / Schoenmaekers, Janna Josephus Anna Oda; Paats, Marthe Sentijna; Dingemans, Anne-Marie Clasina ; Hendriks, Lizza Elisabeth Lucia.

In: Translational Lung Cancer Research, Vol. 9, No. 6, 12.2020, p. 2599-2617.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer

T2 - how to treat and when?

AU - Schoenmaekers, Janna Josephus Anna Oda

AU - Paats, Marthe Sentijna

AU - Dingemans, Anne-Marie Clasina

AU - Hendriks, Lizza Elisabeth Lucia

PY - 2020/12

Y1 - 2020/12

KW - Non-small cell lung cancer (NSCLC)

KW - central nervous system metastases (CNS metastases)

KW - oligometastatic disease

KW - tyrosine kinase inhibitors (TKIs)

KW - DABRAFENIB PLUS TRAMETINIB

KW - POSITIVE SOLID TUMORS

KW - EML4-ALK FUSION GENE

KW - HIGH-DOSE ERLOTINIB

KW - BRAIN METASTASES

KW - OPEN-LABEL

KW - EGFR-MUTATION

KW - LEPTOMENINGEAL METASTASES

KW - CEREBROSPINAL-FLUID

KW - 1ST-LINE TREATMENT

U2 - 10.21037/tlcr-20-459

DO - 10.21037/tlcr-20-459

M3 - Review article

C2 - 33489821

VL - 9

SP - 2599

EP - 2617

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 6

ER -